These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26467209)

  • 1. Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
    Srinivas NR
    Drug Dev Ind Pharm; 2016; 42(6):945-57. PubMed ID: 26467209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
    Kim MG; Kim Y; Jeon JY; Kim DS
    Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
    Tateishi T; Miura M; Suzuki T; Uno T
    Br J Clin Pharmacol; 2008 May; 65(5):693-700. PubMed ID: 18294330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
    Vanhove T; Bouillon T; de Loor H; Annaert P; Kuypers D
    Clin Pharmacol Ther; 2017 Dec; 102(6):989-996. PubMed ID: 28437851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach.
    Cusinato DAC; Martinez EZ; Cintra MTC; Filgueira GCO; Berretta AA; Lanchote VL; Coelho EB
    J Ethnopharmacol; 2019 Dec; 245():112174. PubMed ID: 31442620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
    Wang R; Zhang H; Wang Y; Yu X; Yuan Y
    J Ethnopharmacol; 2016 Mar; 180():87-96. PubMed ID: 26806573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Sep; 62(3):372-6. PubMed ID: 16796706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T; Shimizu M; Sugawara K; Tateishi T
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
    Wilson A; Tirona RG; Kim RB
    Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
    Kim KA; Park PW; Park JY
    Eur J Clin Pharmacol; 2009 Jun; 65(6):609-14. PubMed ID: 19221726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
    Kharasch ED; Bedynek PS; Walker A; Whittington D; Hoffer C
    Clin Pharmacol Ther; 2008 Oct; 84(4):506-12. PubMed ID: 19238656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
    Srinivas NR
    Am J Ther; 2017; 24(4):e405-e418. PubMed ID: 26291590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
    Sakugawa T; Miura M; Hokama N; Suzuki T; Tateishi T; Uno T
    Br J Clin Pharmacol; 2009 May; 67(5):535-40. PubMed ID: 19552748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
    Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.
    Tanveer A; Hussain K; Tasneem H; Arif I; Rashid M; Abbas N; Shamim R; Shah PA; Bukhari NI
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):311-323. PubMed ID: 35061161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.